Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above Two Hundred Day Moving Average – What’s Next?

Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.41 and traded as high as $6.34. Cumberland Pharmaceuticals shares last traded at $6.25, with a volume of 41,099 shares traded.

Analyst Ratings Changes

CPIX has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Wednesday, June 24th. Wall Street Zen downgraded Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Cumberland Pharmaceuticals currently has an average rating of “Sell”.

Cumberland Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.79 and a current ratio of 0.95. The stock’s 50-day moving average is $5.62 and its two-hundred day moving average is $4.43. The stock has a market cap of $88.85 million, a PE ratio of -12.10 and a beta of 0.09.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13). The business had revenue of $9.13 million during the quarter, compared to analyst estimates of $8.50 million. Cumberland Pharmaceuticals had a negative return on equity of 12.01% and a negative net margin of 17.60%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CPIX. XTX Topco Ltd purchased a new stake in Cumberland Pharmaceuticals during the 2nd quarter worth approximately $34,000. Bridgeway Capital Management LLC increased its position in shares of Cumberland Pharmaceuticals by 2.3% during the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock worth $631,000 after acquiring an additional 4,200 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Cumberland Pharmaceuticals by 11.1% in the third quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock valued at $876,000 after acquiring an additional 27,980 shares in the last quarter. Two Sigma Investments LP boosted its holdings in Cumberland Pharmaceuticals by 16.5% in the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after purchasing an additional 5,326 shares during the period. Finally, Geode Capital Management LLC grew its stake in Cumberland Pharmaceuticals by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock worth $427,000 after purchasing an additional 5,653 shares in the last quarter. Hedge funds and other institutional investors own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.